NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
Clinical Trials
24 trialsNCT03973918 2024-10-31
BRAF
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00014443 2023-01-09
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Rush University Medical Center
Phase 2 Terminated
NCT01822275 2022-12-29
GCC 1224
University of Maryland, Baltimore
Phase 2 Terminated
NCT03641326 2022-04-19
Sunitinib in Sarcomas of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02743078 2021-06-02
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
RTOG Foundation, Inc.
Phase 2 Terminated
NCT00006916 2020-10-26
Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Radiation Therapy Oncology Group
Phase 2 Terminated
NCT01186406 2019-02-15
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT01575275 2018-07-31
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01836549 2018-07-20
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Pediatric Brain Tumor Consortium
Phase 2 Terminated
NCT00052715 2018-07-18
Poly-ICLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00238277 2018-06-27
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00112866 2017-06-14
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01310855 2017-05-31
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
Phase 2 Terminated
NCT01122901 2017-05-03
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00436436 2017-03-28
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02394665 2017-01-05
Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
University of Miami
Phase 2 Terminated
NCT00068770 2015-03-18
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01017653 2013-09-04
Panitumumab and Irinotecan for Malignant Gliomas
Duke University
Phase 2 Terminated
NCT01095094 2013-06-10
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00387894 2013-06-04
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
University of California, San Francisco
Phase 2 Terminated
NCT00735436 2013-02-11
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT00848523 2010-07-16
Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
Neurological Surgery, P.C.
Phase 2 Terminated
NCT00365222 2009-01-22
Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated